Conclusion As the multi-hit hypothesis holds, combining the therapeutic approaches of GLP-1 agonists with resmetirom seems like a promising strategy by targeting the multifaceted pathophysiology of MASH, which may lead to improved patient outcomes
With two full phases of clinical trial data already completed, the results speak for themselves record-setting weight loss, dramatic improvements in metabolic markers, and promising impacts on overall healthspan
As we continue to innovate in the field of diabetes drugs, the focus on patient-centric solutions will remain paramount
Southeast Asian J Trop Med Pub Hlth 47: 1335-1342
It's not insulin-rather, it mimics the effects of the glucagon-like peptide-1 (GLP-1) hormone, which helps manage blood glucose levels post-meal
Schedule donation at least 48 hours after your last GLP-1 injection, and ensure you are well-hydrated, have eaten a balanced meal, and are not experiencing active nausea, diarrhea, or dizziness